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Abstract. Plasminogen activator inhibitor 1 (PAI-1), which belongs to the family of serine protease inhibitors  is the 
primary regulator of plasminogen activity. PAI-1 is synthesized as a single-chain glycopeptide and is deposited in the 
platelets in a latent form, from which it is released upon their activation. It is spontaneously converted into stable 
molecules, unless it reacts with proteins from the plasma. As a powerful inhibitor of fibrinolysis, it participates in the 
pathogenesis of endothelial damage, processes of accelerated atherosclerosis and thromboembolism. All the diseases 
of the cardiovascular system which are dominated by the processes of fibrosis and thrombosis lead to an increase in 
PAI-1 in the circulation. In the emergence and development of atherosclerosis, it plays a role not only in the formation 
of intraluminal thrombus but also in neointimal proliferation. PAI-1 is not normally present in kidney tissue, but its 
concentration increases significantly in its acute and chronic kidney disease, thanks to the synthesis by the 
intrarenally localized inflammatory cells. In addition to genetic predisposition, the factors that directly influence the 
production of PAI-1 are the following: glycemia, insulin and various neurohumoral factors. It is not normally present 
in the kidney tissue, but its intrarenal concentration increases significantly in acute and chronic kidney diseases. 
Numerous studies have confirmed the significant role of PAI-1 in the development of diabetes complications. During 
the last decade there has been a growth of interest in the introduction of non-invasive methods or biomarkers that 
would assess the degree of fibrosis in the kidney. Many studies have confirmed association between kidney and heart 
disease. It is not only that these diseases share common risk factors, but many other mechanisms have been suggested. 
Plasminogen activator inhibitor -1 plays a role in the pathogenesis of endothelial damage, processes of fibrosis and 
thrombosis, development of diabetes complications and acute and chronic kidney diseases. 
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Introduction

 
Brakman was the first to describe the existence of an in-
hibitor of tissue plasminogen activator in 1966 and only 
after 20 years of activator inhibitor-1 tissue plasminogen 
activator (PAI-1) was isolated from cultures of endothelial 
cells by which it is named an endothelial type plasminogen 
inhibitor of tissue. It belongs to the superfamily of serine 
protease inhibitors - serpin. It has four different structural 
forms with the conversion of certain regulatory mecha-
nisms of fibrinolytic system. Its structure and site of syn-
thesis (the endothelium, megakaryocytes, endometrium, 
macrophages, mesothelial cells, adipose tissue) were later 
determined. The gene responsible for the synthesis of PAI-
1 was localized to chromosome 7. Once synthesized PAI-1 
accumulates in platelets, it can be found in subendothelial 
matrix and in the bloodstream. Fibrinolytic system includes 
a wide spectrum of proteolytic enzymes and functions in 
the process of hemostasis, tissue remodeling, tumor inva-
sion and angiogenesis. The main enzyme in the system is 
plasminogen activator, plasmin, which is responsible for 
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degradation of soluble fibrin degradation products. Activa-
tion of plasminogen to plasmin is carried out by two types 
of activators: urokinase type plasminogen activator (uPA) 
and tissue-type activator plasminogen (tPA) and fibrin. 
Clearance and its accumulation are regulated by specific 
inhibitors of plasminogen activator of which the main is 
PAI-1. PAI-1 activity-neutralizing factors are XIIa, plasma 
kallikrein, and XIa [1] (Fig. 1). 
 
 
Fig. 1 Schematic presentation of activation of plasminogen 
Roles of PAI-1 
In addition to the role of antiprotease, PAI-1 has a high 
binding affinity for ligands of different receptors. Thus 
it affects cellular functions such as adhesion, migration, 
proliferation and intracellular signaling mechanisms that 
are similar in the cardiac muscle and renal mesangial 
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matrix. Changes in the level of PAI-1 are strictly con-
nected to the traditional and non-traditional risk factors 
and their complications. As an indication of the acute 
phase of inflammation or the acute inflammatory re-
sponse, as well as metabolic control and neurohormonal 
activation, PAI-1 independently or synergistically with 
other pro-inflammatory molecule is a predictor of cardi-
ovascular risk. In the literature it is described that a high 
level of PAI-1 is related to atherosclerosis and increased 
risk for plaque rupture [2]. In contrast to such findings, 
there are data from some researchers that there is profi-
brotic effect of PAI-1 in the affected muscles infarction, 
but also antifibrotic effect in the aging process. 
Fibrinolytic System and Heart Disease 
Decreased fibrinolysis with an increased concentration 
of PAI-1: tPA preformed complex PAI-1 in plasma, 
occurs in patients with coronary heart disease. The 
highest expression in the myocardium According to the 
type of circadian rhythm, the highest expression of PAI-
1 in the myocardium is in the early morning hours at the 
exact time when an acute coronary syndrome exhibits a 
maximum incidence. Locally elevated PAI-1 predis-
poses the occurrence of the acellular thin atherosclerotic 
plaque attaching to the wall of the blood vessel and in-
creasing the risk of rupture. When there is a rupture of 
PAI-1, it is released from the damaged plaque and from 
the platelet and local concentration of PAI-1 is in-
creased by more than 10 times and a clot is formed. In 
recent decades, there have been developed percutaneous 
techniques for the repair of the stenosis of coronary 
blood vessels (including angioplasty, atherectomy, and 
stent implantation). Restenosis is associated with differ-
ent supporting mechanisms involving different hemo-
static factors and there is a slow increase in the concen-
tration of PAI-1[3]. On the other hand, TAFI (thrombin 
activatable fibrinolysis inhibitor) is an antifibrinolytic 
factor whose growth increases with the influence of 
procoagulant stimulus but with contradictory research 
results concerning its association with myocardial in-
farction. It is clear that there is a direct molecular bond 
between the TAFI system with coagulation and fibri-
nolytic cascade [4]. However, the initiation of coagula-
tion under the control of a sound is performed by the 
endothelial release of TFPI (tissue factor pathway in-
hibitor) which limits the activity of the TF / VIIa / Xa 
[5]. The determination of high levels of TAFI and low 
levels of PAI-1 prior to intervention is important to 
identify patients at high risk for restenosis. Increased 
number of late stent thrombosis is explained by the me-
chanical factor such as a posture in a stent in the pene-
tration of the necrotic part of the tissue, biological fac-
tors such as the altered phenotype of endothelial cells 
and gene polymorphism. Genetic polymorphism ex-
plains the relationship between PAI-1 and risk of coro-
nary heart disease. PAI-1 is synthesized and released via 
the sympathetic-adrenal axis for which it is the key me-
diator in the stress-induced thrombosis and hypercoag-
ulability conditions [6] (Fig. 2).  
Fibrinolytic System and Inflammation 
The complex relationship between inflammation and 
thrombosis influences the course of coronary artery dis-
ease in metabolic syndrome. Proinflammatory particles 
stimulate multiple prothrombotic effects and acute cor-
onary syndrome. Cardiovascular diseases with altered 
fibrinolytic system are connected to a raised level of 
PAI-1. Many authors emphasize the special role of the 
fibrinolytic system disfunction in metabolic syndrome 
related to the mechanism of coronary heart disease. The 
changing role of the fibrinolytic system is in connection 
with insulin resistance and visceral obesity, where PAI-
1 plays a crucial role and its concentration rises in the 
blood and coronary plaque in these patients. The most 
common disorder of hemostasis, which occurs in these 
patients is reduced by the level of tissue factor pathway 
inhibitor, an elevated level of TAFI, VWF, fibrinogen, 
Factor VII, VIII and XIII and the vitamin K dependent 
coagulation proteins. Many authors recognize the bi-
directional interaction between the elements of the met-
abolic syndrome and the expression of PAI-1. Adipo-
cyte differentiation in the metabolic syndrome is in-
duced by a set of signaling mechanisms that increase the 
expression of PAI-1 receptor and interfering with the 
signaling mechanisms of the insulin, and thus stimulate 
the formation of obesity [7]. It is assumed that the role 
of PAI-1 in metabolic syndrome is more important. 
Therefore, it is attractive as a target for developing new 
drugs. It has been shown that in the basis of atheroscle-
rosis stands chronic inflammation, and that C-reactive 
protein (CRP) directly promotes the formation of ather-
osclerotic lesion through the interaction of the monocyte 
and endothelial cells by increasing the activity of PAI-1. 
CRP also increases the activity of PAI-1 in the state of 
hyperglycemia. On the other hand, CRP reduces the 
activity of the tissue PA in human endothelial cells 
which shows that CRP stimulates procoagulant effect 
(Fig. 3). CRP via activation of the protein kinase and 
 
Fig. 2. Schematic presentation of the process of fibrinolysis 
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NF-kB affects the expression of PAI-1 and affects he-
modynamic induced migration of smooth muscle cells 
in blood vessels [8]. 
Apart from the acute phase, PAI-1 is increased in con-
ditions of chronic inflammation, which is associated with 
renal disease. This partly explains the development of 
accelerated atherosclerosis in this patient population. Kid-
ney diseases in which intra-renal expressions of PAI-1 are 
increased, are: diabetic nephropathy, focal segmental 
glomerulosclerosis (FSGS), membranous nephropathy, 
chronic allograft nephropathy, thrombotic microangiopa-
thy, arteriolonephrosclerosis, "Crescent" focal necrotizing 
glomerulonephritis, glomerulonephritis. The level of PAI-
1 is correlated with the severity of disease and in chronic 
renal disease, it accumulates in the interstitium [9].  
Fybrinolitic System and Kidney Disease 
It is believed that PAI-1 plays an important role in the 
complex mechanisms of tubulointerstitial renal fibrosis. 
Polymorphism of uric acid affects the plasma concen-
trations of PAI-1 and is linked with insulin resistance, 
level of circulating PAI-1 and activation of RAA sys-
tem. In addition to genetic predisposition, factors which 
directly influence the production of PAI-1 are: glucose, 
insulin and various neurohumoral factors. Numerous 
studies have demonstrated an important role of PAI-1 in 
the development of diabetic complications [10]. Throm-
bin stimulates smooth muscle cells in blood vessels that 
release large amounts of PAI-1. In addition, it is known 
that the expression of the PAI-1 gene product is closely 
related to the differentiation of adipocytes and the phe-
notypic change of smooth muscle cells blood vessels. It 
is accepted that the PAI-1 risk factor for cardiovascular 
events in diseases is related with "bad" habits and life-
style. Fibrosis is important for the development of 
chronic kidney disease. Decreased renal functional re-
serve leads to increased activity of inflammation and 
endothelial dysfunction. These processes increase the 
risk of the occurrence of cardiovascular disease and 
venous thrombosis and are associated with elevated 
levels of PAI-1. Decrease of glomerular filtration 
rate (GFR) increases the level of molecules which are 
markers of hemostasis. In addition, impaired renal 
function contributes to the formation of prothrombotic 
condition indirectly through the electrolyte disturbances 
and acid-base status influencing the change of activity 
of the enzyme coagulation [11]. It was found that ather-
osclerosis and risk of cardiovascular disease are associ-
ated with inflammation and procoagulant state. Patients 
with GFR <60 ml/ min/1.73m2 have 6.5% higher levels 
of PAI-1 in comparison to subjects with GFR> 
90ml/min/1.73m2 which indicates that a disturbance 
homeostasis plays an important role in chronic kidney 
disease [12]. The fifth stage of chronic kidney disease 
has a three times higher risk for cardiovascular events 
compared with the general population while patients on 
chronic hemodialysis have up to 100 times higher risk 
of cardiovascular mortality compared with the general 
population younger than 45 years. Biomarkers of in-
flammation and oxidative stress are predictors of cardi-
ovascular events in patients on chronic hemodialysis. 
During hemodialysis, blood in contact with a dialyser 
activates kallikrein kinin system and induces an in-
flammatory response by activating leukocytes and the 
production of cytokines [13]. Cytokines such as TNF 
alpha, IL 1 beta and IL 6 stimulate the expression of 
PAI-1 of a large physiological fibrinolysis inhibitor in 
vivo [14, 15]. It is well known that a continuous build-
up of fibrin deposition in the renal transplant mecha-
nism leads to chronic graft rejection. The mechanism of 
accumulation of fibrin, tPA is super expressed only in 
the acute phase of rejection. Upregulation of tPA is pre-
sent during the progressive stages of chronic rejection 
and is synchronized with the induction of PAI-1 in the 
graft [16]. This means that the induction of PAI-1 is 
responsible for the accumulation of fibrin resulting in 
chronic irreversible damage and chronic kidney disease. 
Testing of PAI-1 genotype is in correlation with devel-
opment of fibrosis, atrophy of tubules and interstitial 
fibrosis. It has been shown that genetic variation of fi-
brinolytic system affects long-term outcome of kidney 
transplantation. It has been found among people with 
previous acute rejection that G4 homozygous for the 
polymorphism had a significantly higher risk of kidney 
rejection. The conclusion of a number of studies is that 
determination of the genotype PAI-1 prior to transplan-
tation could help to identify patients who are at risk for 
chronic rejection of transplanted kidney [17]. PAI-1 is a 
molecule, which is regulated not only genetically but 
also by metabolic and inflammatory factors, and it is 
known that the level of PAI-1 is correlated with the 
level of decreased function of the graft. 
 
Fig. 3 Schematic presentation of the role of inflammation in the blood vessel reocclusion 
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Conclusion 
Determining prothrombotic biomarkers may help in 
the planning of timely and appropriate preventive 
measures for all patients who are at high risk of adverse 
cardiovascular events. During the last decade there has 
been an increase of interest in the introduction of non-
invasive methods or biomarkers that would assess the 
degree of fibrosis in the kidney. In addition, experi-
mental tests are underway of oral active PAI-1 inhibitor, 
which is a new class of anti-inflammatory agents.  
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